<DOC>
	<DOC>NCT02097446</DOC>
	<brief_summary>- Indication: Benign tumors of ovary(mature teratoma, mucinous cystadenoma, serous cystadenoma) - Intervention: Device ( Test group : Guardix-FL, Control group : Interceed) - Primary Outcome Measure : Anti-adhesion Rate - Assessment : Operative Day(Visit 2), Post-Operative Day+7days(Vist 3), Post-Operative Day+4weeks(Visit4), Post-Operative Day+5weeks(Visit 5)</brief_summary>
	<brief_title>Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy</brief_title>
	<detailed_description />
	<mesh_term>Genital Diseases, Female</mesh_term>
	<criteria>1. The patients who sign the written informed consent 2. Women aged between 18 and 44 3. The patients who are able to participate in clinical trial during the period of study 4. The patients without abnormal figures at the screening laboratory examination 5. The patients expecting ovarian cystectomy for benign ovarian tumor(mature cystic teratoma, Mucinous cystadenoma, serous cystadenoma) 1. The patients who took treatments with medical products which might be barrier to evaluate the effectiveness 2. The patients who took medicine like other antiadhesion, absorbable hemostat and dose of steroid, immunosuppressants 3. The patients with severe drug allergy 4. The patients with infectious disease on abdominal or pelvic cavity 5. The patients who previously participated in another clinical trials within the past 30 days 6. The patients considered inappropriate for the study 7. The pregnant 8. The patients with severe renal disease 9. The patients with severe systemic diseases</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>cystectomy</keyword>
</DOC>